Open the filing on EDGARNEWS RELEASE Exhibit 99.1
GRAIL Reports First Quarter 2026 Financial Results
Q1 Galleri® Revenue Grew 37% Year-Over-Year to $39.8 Million, and Test Volume Increased 50% to More Than 56,000
Announced Plans to Integrate the Galleri Test Into Epic Electronic Health Record Platform to Expand Access Nationwide
New Data From the NHS-Galleri Trial and PATHFINDER 2 Study to be Presented at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
MENLO PARK, Calif. - May 5, 2026 - GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the first quarter of 2026.
Total revenue in the first quarter grew 28% year over year to $40.8 million, and Galleri revenue grew 37% year-over-year to $39.8 million. Galleri test volume for the quarter grew 50% year-over-year to more than 56,000. Net loss for the quarter was $93.2 million. Gross loss was $14.3 million. Non-GAAP adjusted gross profit was $19.7 million, and non-GAAP adjusted EBITDA was $(79.9) million.
“GRAIL continues to execute commercially, with strong volume growth in Q1. We continue to build new partnerships to support demand and were pleased to announce our collaboration with Epic, which will expand access to Galleri for physicians and patients,” said Bob Ragusa, Chief Executive Officer at GRAIL. “We are looking forward to our upcoming presentations of detailed results from our 35,000 PATHFINDER 2 study and the 140,000 NHS-Galleri trial, which were accepted for presentation at the 2026 ASCO Annual Meeting in late May.”
For the three months ended March 31, 2026, as compared to the three months ended March 31, 2025, GRAIL reported:
- Revenue: Total revenue, comprised of screening and development services revenue, was $40.8 million, an increase of $8.9 million or 28%.
- Net loss: Net loss was $93.2 million, an improvement of $13.0 million or 12%.
- Gross loss: Gross loss was $14.3 million, an improvement of $5.6 million or 28%.
- Adjusted gross profit: Adjusted gross profit was $19.7 million, an increase of $5.4 million or 38%.
- Adjusted EBITDA: Adjusted EBITDA was $(79.9) million, an improvement of $18.8 million or 19%.
Cash position: Cash, cash equivalents, and short-term marketable securities totaled $823.1 million as of March 31, 2026.
See “Non-GAAP Disclosure” and the associated reconciliations for important information about our use of non-GAAP measures.
Recent business highlights include:
- The Premarket Approval (PMA) application for Galleri was submitted to the U.S. Food and Drug Administration (FDA) in January and accepted by FDA for review. The PMA submission is focused on test performance and safety results from 25,000 consented participants in the U.S.-based PATHFINDER 2 study with one year of follow up and from the prevalent screening round (first year) of the 140,000 participant NHS-Galleri trial, the largest, and only, randomized, controlled intended use trial of any multi-cancer early detection (MCED) test. The submission is also supported by a bridging analysis to compare performance of the version of Galleri used in clinical trials to the updated version that has been submitted to the FDA for premarket approval.
- Announced planned integration of the Galleri test into Epic’s electronic health record (EHR) platform to expand access nationwide. Epic is a leading EHR platform used by many large and advanced health systems. Integration through Epic Aura will allow health systems and their healthcare providers to order the Galleri test directly at the point of care, receive structured results, and manage patient follow-up seamlessly within their existing native EHR and within their existing clinical workflows. Broad availability in Epic EHR platform is expected by the end of 2026.
- Data presentations at the American Association of Cancer Research (AACR) 2026 Annual Meeting in April:
- An analysis of the association between emergency department involvement in the diagnosis of cancer and overall survival across different cancer types in the Medicare population. Emergency department involvement was associated with a significant fraction of overall mortality in patients with cancer. Emergency department involvement at diagnosis remained a strong independent predictor of mortality after adjusting for sociodemographics, comorbidities, and stage at diagnosis.
- An analysis of adherence to mammography screening before and after MCED testing. showed that women who received a negative MCED result maintained high adherence to guideline-recommended mammography, with >80% undergoing screening in the 24 months after MCED testing, similar to rates in the 24 months before testing. These findings suggest that MCED testing does not negatively impact participation in guideline-recommended cancer screening.
- Announced new data from both the NHS-Galleri trial and the PATHFINDER 2 study will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 29 - June 2, 2026:
- Detailed NHS-Galleri Trial results will be presented as a late-breaking abstract in an oral presentation during a clinical science symposium on Saturday, May 30.
- Final PATHFINDER 2 study results will be presented as a late-breaking abstract in an oral presentation on Sunday, May 31.
- More than 174,000 participants enrolled across both studies, demonstrating the scientific rigor of the Galleri clinical development program.
Conference Call and Webcast
A webcast and conference call will be held today, May 5, 2026, at 1:30 p.m. PT / 4:30 p.m. ET. Individuals interested in listening to the conference call may access it on the investor relations section of GRAIL’s website at investors.grail.com.
A replay of the webcast will be available on GRAIL’s website for 30 days.
About GRAIL
GRAIL, Inc. is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL’s targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom. GRAIL’s common stock is listed under the ticker symbol “GRAL” on the Nasdaq Stock Exchange.
For more information, visit grail.com.
About Galleri®
The Galleri multi-cancer early detection test is a proactive tool to screen for cancer. With a simple blood draw, the Galleri test can identify DNA shed by cancer cells, which can act as a unique "fingerprint" of cancer, to help screen for some of the deadliest cancers that don’t have recommended screening today, such as pancreatic, esophageal, ovarian, liver, and others. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer, giving healthcare providers a roadmap of where to explore further. The Galleri test requires a prescription from a licensed healthcare provider and should be used in addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific antigen (PSA) test, or cervical cancer screening. The Galleri test is recommended for adults with an elevated risk for cancer, such as those aged 50 or older.
For more information, visit galleri.com.
Laboratory/Test Information
GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the U.S. Food and Drug Administration. GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.
Non-GAAP Disclosure
In addition to our financial results provided throughout this press release that are determined in accordance with U.S. generally accepted accounting principles (“GAAP”), this press release also includes financial measures that are not calculated in accordance with GAAP. Our non-GAAP financial disclosure includes Adjusted Gross Profit and Adjusted EBITDA. We encourage investors to carefully consider our results under GAAP in conjunction with our supplemental non-GAAP information and the reconciliation between these presentations.
- Adjusted Gross Profit is a key performance measure that our management uses to assess our operational performance, as it represents the results of revenues and direct costs, which are key components of our operations. We believe that this non-GAAP financial measure is useful to investors and other interested parties in analyzing our financial performance because it reflects the gross profitability of our operations, and excludes the costs associated with our sales and marketing, product development, general and administrative activities and the impact of our financing methods and income taxes. We calculate Adjusted Gross Profit as gross profit (loss) (as defined below) adjusted to exclude amortization of intangible assets and stock-based compensation allocated to cost of revenue. Adjusted Gross Profit should be viewed as a measure of operating performance that is a supplement to, and not a substitute for, operating income or loss from operations, net earnings or loss and other GAAP measures of income (loss) or profitability. Gross profit (loss) (as defined below) is the most directly comparable financial measure calculated in accordance with GAAP.
- Adjusted EBITDA is a key performance measure that our management uses to assess our financial performance and is also used for internal planning and forecasting purposes. We believe that this non-GAAP financial measure is useful to investors and other interested parties in analyzing our financial performance because it provides a comparable overview of our operations across historical periods. In addition, we believe that providing Adjusted EBITDA, together with a reconciliation of net loss to Adjusted EBITDA, helps investors make comparisons between our company and other companies that may have different capital structures, different tax rates, different operational and ownership histories, and/or different forms of employee compensation. Adjusted EBITDA is used by our management team as an additional measure of our performance for purposes of business decision-making, including managing expenditures. Period-to-period comparisons of Adjusted EBITDA help our management identify additional trends in our financial results that may not be shown solely by period-to-period comparisons of net income (loss) or income (loss) from operations. Our management recognizes that Adjusted EBITDA has inherent limitations because of the excluded items, and may not be directly comparable to similarly titled metrics used by other companies.
The Company defines Adjusted EBITDA as net loss adjusted for amortization of intangible assets, stock-based compensation, depreciation, benefit from income taxes, interest income and restructuring expenses. These adjustments include non-cash items, significant non-recurring charges and/or other non-operating expenses that we do not believe are indicative of ongoing or future business operations.
Adjusted EBITDA should be viewed as a measure of operating performance that is a supplement to, and not a substitute for, operating income or loss from operations, net earnings or loss and other U.S. GAAP measures of income (loss). Additionally, it is not intended to be a measure of free cash flow for management’s discretionary use, as it does not consider certain cash requirements such as interest and tax payments. Further, our definition of Adjusted EBITDA may differ from similarly titled measures used by other companies and therefore may not be comparable among companies. Net loss is the most directly comparable financial measure calculated in accordance with GAAP.
Full reconciliation of these non-GAAP measures to the most comparable GAAP measures is set forth in tabular form following the Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Operations.
Forward-Looking Statements
This press release contains forward-looking statements. In some cases, you can identify these statements by forward-looking words such as “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “should,” “would,” or “will,” the negative of these terms, and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties, and assumptions about us, may include expectations and projections of our future financial performance, future tests or products, patient awareness of our products, technology, clinical studies, planned presentations at upcoming conferences, safety results, regulatory compliance, potential market opportunity, anticipated growth strategies, restructuring costs, sufficiency of cash on hand to finance our business, cost savings, budgets and strategies, satisfaction of closing conditions in the Samsung collaboration, planned integration with EHR systems, and growth and anticipated trends in our business.
These statements are only predictions based on our current expectations and projections about future events and trends. There are important factors that could cause our actual results, level of activity, performance, or achievements to differ materially and adversely from those expressed or implied by the forward-looking statements, including those factors and numerous associated risks discussed under the sections entitled “Risk Factors” in our Annual Report on Form 10-K for the period ended December 31, 2025 and in the Quarterly Report on Form 10-Q that we plan to file for the period ended March 31, 2026. Moreover, we operate in a dynamic and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results, level of activity, performance, or achievements to differ materially and adversely from those contained in any forward-looking statements we may make.
Forward-looking statements relate to the future and, accordingly, are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Although we believe the expectations and projections expressed or implied by the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Except to the extent required by law, we undertake no obligation to update any of these forward-looking statements after the date of this press release to conform our prior statements to actual results or revised expectations or to reflect new information or the occurrence of unanticipated events.
GRAIL Contacts
Corporate Communications
Kristen Davis
Trish Rowland pr@grail.com
Condensed Consolidated Balance Sheets
(amounts in thousands, except share and per share data)
| March 31, 2026 | December 31, 2025 |
|---|
| Assets | | |
| Current assets: | | |
| Cash and cash equivalents | $69,344 | $249,727 |
| Short-term marketable securities | 753,761 | 654,703 |
| Accounts receivables, net | 20,345 | 18,295 |
| Supplies | 17,194 | 16,017 |
| Prepaid expenses and other current assets | 16,703 | 15,107 |
| Total current assets | 877,347 | 953,849 |
| Property and equipment, net | 47,853 | 51,813 |
| Operating lease right-of-use assets | 48,055 | 52,070 |
| Restricted cash | 6,974 | 6,974 |
| Intangible assets, net | 1,815,972 | 1,850,556 |
| Other non-current assets | 7,273 | 6,753 |
| Total assets | $2,803,474 | $2,922,015 |
| Liabilities and stockholders’ equity | | |
| Current liabilities: | | |
| Accounts payable | $4,668 | $2,083 |
| Accrued liabilities | 58,267 | 63,945 |
| Operating lease liabilities, current portion | 9,939 | 11,715 |
| Other current liabilities | 1,835 | 1,927 |
| Total current liabilities | 74,709 | 79,670 |
| Operating lease liabilities, net of current portion | 41,091 | 43,148 |
| Deferred tax liability, net | 184,035 | 218,583 |
| Other non-current liabilities | 2,953 | 2,752 |
| Total liabilities | 302,788 | 344,153 |
| Preferred stock, par value of $0.001 per share; 50,000,000 shares authorized, no shares issued and outstanding as of March 31, 2026 and December 31, 2025 | - | - |
| Common stock $0.001 par value per share, 1,500,000,000 shares authorized as of March 31, 2026 and December 31, 2025 and 41,134,219 and 40,331,360 shares issued and outstanding as of March 31, 2026 and December 31, 2025 | 41 | 40 |
| Additional paid-in capital | 12,803,640 | 12,786,848 |
| Accumulated other comprehensive income | 1,873 | 2,655 |
| Accumulated deficit | (10,304,868) | (10,211,681) |
| Total stockholders' equity | 2,500,686 | 2,577,862 |
| Total liabilities and stockholders' equity | $2,803,474 | $2,922,015 |
Condensed Consolidated Statements of Operations
(amounts in thousands, except share and per share data)
| Three Months Ended | |
|---|
| March 31, 2026 | March 31, 2025 |
|---|
| Revenue: | | |
| Screening revenue | $39,832 | $29,133 |
| Development services revenue | 953 | 2,704 |
| Total revenue | 40,785 | 31,837 |
| Costs and operating expenses: | | |
| Cost of screening revenue (exclusive of amortization of intangible assets) | 21,244 | 17,123 |
| Cost of development services revenue | 376 | 1,171 |
| Cost of revenue - amortization of intangible assets | 33,472 | 33,472 |
| Research and development | 48,021 | 53,625 |
| Sales and marketing | 30,668 | 34,979 |
| General and administrative | 42,769 | 45,074 |
| Total costs and operating expenses | 176,550 | 185,444 |
| Loss from operations | (135,765) | (153,607) |
| Other income: | | |
| Interest income | 7,986 | 7,779 |
| Other income (expense), net | 256 | (584) |
| Total other income, net | 8,242 | 7,195 |
| Loss before income taxes | (127,523) | (146,412) |
| Benefit from income taxes | 34,336 | 40,199 |
| Net loss | $(93,187) | $(106,213) |
| Net loss per share - Basic and Diluted | $(2.29) | $(3.10) |
| Weighted-average shares of common stock used in computing net loss per share: | 40,640,879 | 34,308,435 |
Reconciliation of GAAP to Non-GAAP Financial Measures
(amounts in thousands)
| Three Months Ended | |
|---|
| March 31, 2026 | March 31, 2025 |
|---|
| Gross loss | $(14,307) | $(19,929) |
| Amortization of intangible assets | 33,472 | 33,472 |
| Stock-based compensation | 533 | 762 |
| Adjusted Gross Profit | $19,698 | $14,305 |
Gross loss is calculated as total revenue less cost of screening revenue (exclusive of amortization of intangible assets), cost of development services revenue and cost of revenue - amortization of intangible assets.
Reconciliation of GAAP to Non-GAAP Financial Measures
(amounts in thousands)
| Three Months Ended | |
|---|
| March 31, 2026 | March 31, 2025 |
|---|
| Net loss | $(93,187) | $(106,213) |
| Adjusted to exclude the following: | | |
| Amortization of intangible assets | 34,584 | 34,584 |
| Stock-based compensation | 16,793 | 16,211 |
| Depreciation | 4,210 | 4,695 |
| Benefit from income tax expense | (34,336) | (40,199) |
| Interest income | (7,986) | (7,779) |
| Restructuring | - | (34) |
| Adjusted EBITDA | $(79,922) | $(98,735) |
Represents amortization of intangible assets, including developed technology and trade names.
Contacts
Alex Dobbin
Alexis Tosti ir@grail.com